Market For Sanofi And Regeneron’s Zaltrap Could Be Limited
This article was originally published in The Pink Sheet Daily
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.
You may also be interested in...
Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs
Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.
Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term
The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.
Side Effects Will Pressure Price Of Sanofi’s Zaltrap In Germany
Germany’s IQWiG could not fault Sanofi’s Zaltrap on clinical effectiveness in colorectal cancer, but its identification of serious adverse incidents is likely to depress the drug’s price there.